(Reuters) – The European Medicines Agency’s human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK’s blood cancer drug Blenrep.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shounak Dasgupta)
